Anti-RUNX1 / AML1 抗体 (ab35962)
Key features and details
- Rabbit polyclonal to RUNX1 / AML1
- Suitable for: WB
- Reacts with: Human
- Isotype: IgG
リコンビナント抗体で、ロット間での高い再現性を実現
- 異なるロット間での安定した再現性
- 容易なスケールアップ
- 評価試験による特異性の確認済み
- 倫理基準に準拠 - アニマル・フリーの生産
製品の概要
-
製品名
Anti-RUNX1 / AML1 antibody
RUNX1 / AML1 一次抗体 製品一覧 -
製品の詳細
Rabbit polyclonal to RUNX1 / AML1 -
由来種
Rabbit -
アプリケーション
適用あり: WBmore details -
種交差性
交差種: Human
交差が予測される動物種: Mouse, Rat, Chicken
-
免疫原
Synthetic peptide conjugated to KLH derived from within residues 400 to the C-terminus of Human RUNX1/ AML1.
Immunogen の所有権に関して (Peptide available as ab38695.) -
特記事項
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
バッファー
pH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 98.98% PBS, 1% BSA
Batches of this product that have a concentration < 1mg/ml may have BSA added as a stabilising agent. If you would like information about the formulation of a specific lot, please contact our scientific support team who will be happy to help. -
Concentration information loading... -
精製度
Immunogen affinity purified -
ポリ/モノ
ポリクローナル -
アイソタイプ
IgG -
研究分野
関連製品
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab35962の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
| アプリケーション | Abreviews | 特記事項 |
|---|---|---|
| WB | (2) |
Use a concentration of 0.25 µg/ml. Detects a band of approximately 53 kDa (predicted molecular weight: 49 kDa).
|
| 特記事項 |
|---|
|
WB
Use a concentration of 0.25 µg/ml. Detects a band of approximately 53 kDa (predicted molecular weight: 49 kDa). |
ターゲット情報
-
機能
CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits MYST4-dependent transcriptional activation. -
組織特異性
Expressed in all tissues examined except brain and heart. Highest levels in thymus, bone marrow and peripheral blood. -
関連疾患
Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.
Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.
Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.
Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.
Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.
Defects in RUNX1 are the cause of familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]. FPDMM is an autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia.
Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.
Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16. -
配列類似性
Contains 1 Runt domain. -
ドメイン
A proline/serine/threonine rich region at the C-terminus is necessary for transcriptional activation of target genes. -
翻訳後修飾
Phosphorylated in its C-terminus upon IL-6 treatment. Phosphorylation enhances interaction with MYST3.
Methylated. -
細胞内局在
Nucleus. - Information by UniProt
-
参照データベース
- Entrez Gene: 861 Human
- Entrez Gene: 12394 Mouse
- Entrez Gene: 50662 Rat
- Omim: 151385 Human
- SwissProt: Q01196 Human
- SwissProt: Q03347 Mouse
- SwissProt: Q63046 Rat
- Unigene: 149261 Human
see all -
別名
- Acute myeloid leukemia 1 antibody
- Acute myeloid leukemia 1 protein antibody
- alpha subunit core binding factor antibody
see all
画像
-
Western blot - Anti-RUNX1 / AML1 antibody (ab35962)All lanes : Anti-RUNX1 / AML1 antibody (ab35962) at 1 µg/ml
Lane 1 : Jurkat nuclear extract lysate (ab14844)
Lane 2 : MOLT4 (Human acute lymphoblastic leukemia cell line) Whole Cell Lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/10000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 49 kDa
Observed band size: 52,54,55 kDa why is the actual band size different from the predicted?
Additional bands at: 47 kDa, 75 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 10 seconds -
Western blot - Anti-RUNX1 / AML1 antibody (ab35962)RUNX2 recombinant protein full length, with N-terminal HIS tag, expressed in E.Coli.
RUNX3 overexpression and empty vector control lysates created in HEK293T cells. The protein contains a C-terminal DDK tag.
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (20)
ab35962 は 20 報の論文で使用されています。
- Jeon SB et al. CD34dim cells identified as pluripotent stem cell-derived definitive hemogenic endothelium purified using bone morphogenetic protein 4. Cell Prolif 56:e13366 (2023). PubMed: 36478274
- Yuan R et al. Identification of a Novel Angiogenesis Signalling circSCRG1/miR-1268b/NR4A1 Pathway in Atherosclerosis and the Regulatory Effects of TMP-PF In Vitro. Molecules 28:N/A (2023). PubMed: 36770940
- Issa H et al. Nanoparticle-mediated targeting of the fusion gene RUNX1/ETO in t(8;21)-positive acute myeloid leukaemia. Leukemia 37:820-834 (2023). PubMed: 36823395
- Masuda T et al. RUNX1 transactivates BCR-ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia. Cancer Sci 113:529-539 (2022). PubMed: 34902205
- Eagle K et al. An oncogenic enhancer encodes selective selenium dependency in AML. Cell Stem Cell 29:386-399.e7 (2022). PubMed: 35108519